Navigation Links
Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
Date:2/7/2008

SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that data from the Phase II trial of its novel secretory phospholipaseA2 inhibitor Varespladib (A-002) for the treatment of coronary heart disease will be presented as a late breaker at the 2008 American College of Cardiology 57th Annual Scientific Session on Monday, March 31, 2008 in Chicago, Illinois.

The Phase II trial known as PLASMA (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was a reduction in secretory phospholipase A2 (sPLA2). The study also evaluated the effect of Varespladib on cholesterol levels (LDL-C, non-HDL and total cholesterol) as well as inflammation in patients with stable coronary heart disease.

PLASMA Late-Breaker Trial Data Presentation:

Date/Time: Monday, March 31 from 2:30-2:45pm.

Title/Author: Effects of a Selective Inhibitor of Secretory

Phospholipase A2 on Low Density Lipoproteins and Inflammatory Pathways,

Robert S. Rosenson, MD, Director, Lipoprotein Disorders and Clinical

Atherosclerosis Research, Division of Cardiovascular Medicine at the

University of Michigan, for the PLASMA Investigators.

Location: McCormick Place, Vista Room S406

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and a
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
2. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
3. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
4. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
5. Toxoplasma infection increases risk of schizophrenia, study suggests
6. New Heart Pump Shows Promise in Trial
7. Trial to Test Gene Therapy for Angina in Women
8. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. MDS Pharma Services Wins Award for Management of Global Malaria Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Fit Body Boot Camp in Orlando owners ... camp in order to support Orlando resident, Brent Snyder, who ... hosted the Brent Can Breathe fundraiser on June 1st ... participants and collected over $700. , Officially called Brent Can ... held for Orlando local Brent Snyder, 24, whose last boot ...
(Date:6/19/2013)... 2013 North American Seminars combines ... course with an online continuing education course ... occupational therapists. , The two day ... an online continuing education course will ... solving skills needed to evaluate and treat dizziness ...
(Date:6/19/2013)... MA (PRWEB) June 19, 2013 ... collaboration and sensor machine software, today announced it ... for its Decentralized Fusion Engine technology. The ... and the acquisition of key strategic partnerships. ... and wireless collaboration and machine-to-machine (M2M) software products ...
(Date:6/19/2013)... The reason for the popularity of the Gorilla Grow ... 4x8 flood tray inside the 5’x9’ and have a one ... addition, Gorilla Grow Tents are more like grow rooms than ... strongest grow tents on the market, Gorilla Grow Tents, have ... , Gorilla Grow Tents are made for professionals but still ...
(Date:6/19/2013)... Tornadoes and their devastating aftermath have increased ... fallen victim to these deadly storms find it hard ... protected families and corporations from natural and man-made disasters ... in the philosophy of providing a storm shelter that ... people to stand up, with light and a battery-operated ...
Breaking Medicine News(10 mins):Health News:Fit Body Boot Camp in Orlando Held Successful “Brent Can Breathe” Charity Boot Camp with Proceeds Going to Support Orlando Local Brent Snyder with Cystic Fibrosis 2Health News:New Evidence Based Information on Treatment for Over 8 Million People in the U.S. Affected With Disorders of the Vestibular System 2Health News:Blueforce Awarded Patent for Decentralized Sensor Fusion 2Health News:Stealth Grow Tent Brand’s Popularity Rises 2Health News:Radius Engineering International Inc. Tornado-Resistant Storm Shelters 2
... & Science University Cancer Institute researchers have found the ... cancer tumors in mice, which they hope will translate ... The study was presented today at the 50th annual ... Boston. , Principal investigator Marka Crittenden, M.D., Ph.D., and ...
... biology at the systems level is difficult, especially when ... organisms in a biofilm. Scientists must be able to ... samples. , At Georgia Tech, researchers from the Colleges ... the Center for Bio-Imaging Mass Spectrometry (BIMS), which aims ...
... than 13 millimeters in width twice as likely to burst, ... The risk of a brain aneurysm rupturing over time depends ... a new Mayo Clinic study. , The international study ... brain had a slightly higher risk of rupture than those ...
... CREEK, Calif., Sept. 25 Longs Drugs,(NYSE: LDG ... 400 stores,in three Western states to help residents of ... the annual flu season. Longs is,offering several convenient options ... Select Longs Drugs pharmacies will provide vaccinations to anyone,over ...
... More and ... Milk Their Diets, NASHVILLE, Tenn., Sept. 25 The ... -- which seem to go in,and out of fashion like shoulder pads and ... 27 percent of,Nashville residents -- remain overweight or obese., A new campaign ...
... at an all-time high, a recent study by the Centers ... getting annual mammograms,is declining. To help address this issue, Ellen ... up to issue a call to action for women,nationwide to ... through the "One A Day Women,s Wake-Up Call" program., ...
Cached Medicine News:Health News:Bio-imaging mass spectrometry techniques reveal molecular details about complex systems 2Health News:Bio-imaging mass spectrometry techniques reveal molecular details about complex systems 3Health News:Bio-imaging mass spectrometry techniques reveal molecular details about complex systems 4Health News: Brain Aneurysm Rupture Risk Tied to Location, Size 2Health News:Longs Drug Announces Immunization Program for the 2008/2009 Flu Season 2Health News:Longs Drug Announces Immunization Program for the 2008/2009 Flu Season 3Health News:Longs Drug Announces Immunization Program for the 2008/2009 Flu Season 4Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Video: One A Day(R) and Ellen DeGeneres Team Up to Deliver a Message to Women About Breast Cancer Through The 'One A Day Women's Wake-Up Call' Program 2Health News:Video: One A Day(R) and Ellen DeGeneres Team Up to Deliver a Message to Women About Breast Cancer Through The 'One A Day Women's Wake-Up Call' Program 3
(Date:6/19/2013)... 19, 2013 DST Health Solutions, LLC (DSTHS), ... health plans, integrated delivery systems, and health care providers, ... Management Service (MDMS) has jumped significantly. ... the pricing of medical prescription drug claims, MDMS ... their medical drug claims processes. As specialty drug demand ...
(Date:6/19/2013)... 2013  This year alone, The Leukemia & Lymphoma ... with one goal in mind: Discovering lifesaving therapies for ... (TNT), a flagship LLS fundraising campaign and the world,s ... its landmark 25 th anniversary. To date, TNT ... research to discover and deliver breakthrough cancer treatments that ...
(Date:6/19/2013)... Calif. , June 19, 2013  Omnicell, ... provider of medication and supply management solutions and ... it was named the number one overall pharmacy ... & Infrastructure Report. KLAS, a leading independent healthcare ... automation equipment vendors in its annual rankings. Omnicell ...
Breaking Medicine Technology:Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4
... a biotechnology company developing evidence-based cobiotic™ products that modify ... to support health and well-being, today announced that it ... also announced that the company is initiating a clinical ... being developed for the prediabetic population to support maintenance ...
... (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics ... financial results for 2012.  For the ... loss of $0.8 million, or $0.02 per share. Weighted-average ... reported collaboration income of $0.2 million during the quarter ...
Cached Medicine Technology:NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels 2NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels 3Nile Therapeutics Reports 2012 First Quarter Financial Results 2Nile Therapeutics Reports 2012 First Quarter Financial Results 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: